RUNX2 and osteosarcoma: Kim et al. affirmed the high expression levels of RUNX2 in osteosarcoma and identified it as a key transcription factor that sustains tumor cell survival, modulating a range of downstream target genes such as MYC through the induction of SOX9 and interactions with JMJD1C [64].